**Question:** Longest acting Insulin among the following

A. Insulin Aspart
B. Insulin Glargine
C. Insulin Detemir
D. Insulin Glulisine

**Core Concept:** Insulin is a hormone produced by the pancreas that regulates glucose levels in the blood by facilitating the uptake of glucose by cells, particularly in the liver, muscle, and adipose tissues. Insulin analogs are synthetic forms of insulin that differ from regular human insulin in structure, half-life, or mode of action, resulting in altered pharmacokinetics and pharmacodynamics.

**Why the Correct Answer is Right:** Insulin Glargine is a long-acting insulin analog that has a slow absorption rate and a prolonged duration of action. It is a human insulin analog with two additional arginine residues at positions B31 and B32, which increase its solubility and allow for a more consistent absorption rate over time. Insulin Glargine is a basal insulin used for the management of type 1 and type 2 diabetes, as it provides a stable and prolonged basal insulin level, helping to maintain glucose homeostasis throughout the day and night.

**Why Each Wrong Option is Incorrect:**

A. Insulin Aspart (Rapid-acting insulin analog): This insulin is a rapid-acting analog, which means it has a shorter half-life and is used for the management of post-prandial hyperglycemia or mealtime insulin in diabetes. It is not suitable for basal insulin requirements.

B. Insulin Glargine (Basal insulin): While insulin Glargine is indeed a basal insulin, option B is incorrect because Insulin Glargine has a longer duration of action than the other options, making it less suitable as a rapid-acting insulin.

C. Insulin Detemir (Basal insulin): Insulin Detemir is another long-acting insulin analog, but the reason this option is incorrect is that it has a slightly shorter duration of action than insulin Glargine, making it less effective in maintaining a stable glucose level throughout the day and night.

D. Insulin Glulisine (Rapid-acting insulin analog): Insulin Glulisine is a rapid-acting insulin analog, which is designed for post-prandial hyperglycemia management. It has a shorter half-life than insulin Glargine and is not suitable for basal insulin requirements.

**Clinical Pearl:** In clinical practice, the choice of insulin type depends on the patient's specific needs and lifestyle. Insulin Glargine is preferred in patients requiring long-lasting basal insulin coverage, while insulin Glulisine is used for post-prandial insulin therapy.